Haimiao Yang

发表

A randomized, open-label, two-cycle, two-crossover phase I clinical trial comparing the bioequivalence and safety of afatinib and Giotrif^® in healthy Chinese subjects

Xin-Ning Qu, Lixiu Zhang, Ying Wang, 2022, Journal of Cancer Research and Clinical Oncology.

A randomized, open-label, single-dose, two-cycle crossover study to evaluate the bioequivalence and safety of lenvatinib and Lenvima® in Chinese healthy subjects

Xin-Ning Qu, Tianying Chang, Q. Ren, 2022, Expert opinion on investigational drugs.

A randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and Xeljanz® in Chinese healthy subjects.

Yicheng Zhao, Xin-Ning Qu, Jing Lan, 2022, International immunopharmacology.

A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects

Yicheng Zhao, Zeyu Wang, Lixiu Zhang, 2022, Expert opinion on drug metabolism & toxicology.

Biochanin A as an α-hemolysin inhibitor for combating methicillin-resistant Staphylococcus aureus infection

J. Guan, Wu Song, Yicheng Zhao, 2021, World Journal of Microbiology and Biotechnology.

Pharmacokinetics and safety of the two oral cefaclor formulations in healthy chinese subjects in the fasting and postprandial states

Xin-Ning Qu, Peng Li, Q. Ren, 2022, Frontiers in Pharmacology.

A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta® in healthy Chinese male subjects

Yanli Wang, Zeyu Wang, Xin-Ning Qu, 2021, Expert opinion on biological therapy.

Overexpression of estrogen receptor beta alleviates the toxic effects of beta-amyloid protein on PC12 cells via non-hormonal ligands☆

Yan Fu, L. Si, W. Deng, 2012, Neural regeneration research.

Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta® in Healthy Chinese Male Volunteers

Xinran Ren, Yicheng Zhao, Yanli Wang, 2021, Frontiers in Pharmacology.

Quercetin Reduces the Virulence of S. aureus by Targeting ClpP to Protect Mice from MRSA-Induced Lethal Pneumonia

J. Guan, Heming Wang, Yishen Qu, 2022, Microbiology spectrum.

Pharmacokinetics and bioequivalence of two pomalidomide capsules in healthy chinese subjects under fasting and fed conditions

Tianying Chang, Q. Ren, Jinling Xue, 2022, Investigational New Drugs.

Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trial

Xin-Ning Qu, Xiuge Wang, Tianying Chang, 2023, Expert review of clinical pharmacology.

Improved Antiviral Activity of Classical Swine Fever Virus-Targeted siRNA by Tetrahedral Framework Nucleic Acid-Enhanced Delivery.

G. Song, Z. Dai, Tao-Tao Liu, 2021, ACS applied materials & interfaces.

Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects

Q. Ren, Yingzi Cui, Guang-ping Liu, 2023, Expert opinion on investigational drugs.

The Protective Effect of Shuxin Shengmai Dan on Myocardial Ischemia-Reperfusion Injury in Rats

Yicheng Zhao, Wei Wang, Z. Hao, 2020 .

A randomized, double-blind, single-dose, two-way, parallel phase I clinical study comparing the pharmacokinetics and safety of adalimumab injecta and Humira® in healthy Chinese male volunteers

Xinran Ren, Yanli Wang, Xin-Ning Qu, 2021, Expert opinion on biological therapy.

The Efficacy and Safety of Shen Guo Lao Nian Granule for Common Cold of Qi-Deficiency Syndrome: Study Protocol for a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase II Clinical Trial

Wei Liu, Hongli Jiang, B. Mao, 2017, Evidence-based complementary and alternative medicine : eCAM.

Pharmacokinetics and bioequivalence of sunitinib and Sutent® in Chinese healthy subjects: an open-label, randomized, crossover study

Lixiu Zhang, Guang-ping Liu, Yanli Wang, 2023, Frontiers in pharmacology.

A randomized, single-blind, single-dose, parallel-group study in healthy subjects to demonstrate the pharmacokinetic equivalence of trastuzumab and its biosimilar

Jinling Xue, Yanli Wang, Zhengzhi Liu, 2023, Expert opinion on drug metabolism & toxicology.